Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion

Cosmos Health reported preliminary nine-month 2026 revenue of approximately $54.3 million, up 19%, and reaffirmed full-year revenue guidance of more than $90 million, up approximately 38%. It expects fourth-quarter revenue of at least $35.7 million, up approximately 81% year over year; U.S. e-commerce is expected to contribute approximately $15 million in revenue and $10.5 million in gross profit. The company also reported more than 5.1 million shares repurchased for approximately $1.1 million and said total liabilities fell 13.3% in the first half of 2026.

Analysis

The key underwriting question is conversion, not the growth rate: a unit pipeline is not booked revenue, and subscription count is not proof of durable, low-churn demand. The claimed e-commerce gross profit contribution would make that channel an important driver of the Q4 outlook, but it needs reconciliation to reported revenue, returns, acquisition costs, and cash collection. A miss in any of those could expose how much of the headline growth is repeatable versus launch-driven.

Near term, preliminary figures may support momentum, but the release is company-reported and lacks audited results, segment economics, and cash-flow detail. Over 1–3 months, the decisive catalyst is the full-year filing: revenue recognition, gross-margin mix, receivables/inventory, and whether the CMO pipeline converts to customer orders. The non-core asset estimate may provide optionality, but real estate and digital assets are not cash until sold; a discount to stated value or slow monetization would weaken the balance-sheet narrative. Over 6–18 months, proprietary-brand expansion and CMO utilization could improve operating leverage, while the weight-management device remains an R&D option, not a demonstrated counterweight to established drug-based therapies.

Contrarian read: the growth outlook may be directionally real yet still be overvalued by investors if concentrated in a fast-scaling channel with unproven retention or if growth consumes working capital. Conversely, a verified step-up in cash conversion would make the breadth of growth more valuable than a headline-only reading suggests.

Key Decisions for Investors

• Do not chase COSM solely on the preliminary release. Treat the full-year filing as the entry catalyst; verify segment revenue, gross profit, operating cash flow, receivables/inventory, and e-commerce customer acquisition and repeat-purchase data.
• Conditional long: consider a small, staged COSM position only if audited results support the outlook and cash conversion improves alongside revenue. Falsify the thesis if reported Q4 revenue materially misses the preliminary indication, gross profit fails to track the claimed channel contribution, or working-capital outflows absorb the growth.
• Keep the CMO pipeline on watch rather than valuing it as backlog. Upgrade the thesis only with evidence of conversion into disclosed orders and recognized revenue; a decline in pipeline units or lack of conversion over the next few reporting periods weakens the manufacturing-growth case.
• Assign no material value to the non-core asset cushion until there are completed sales and disclosed net proceeds. Monitor proceeds, liabilities, and share count; the repurchase headline alone is not evidence of per-share value creation.
• Treat CCX0722 as speculative R&D optionality, not a near-term earnings driver. Reassess only on concrete development, regulatory, or efficacy milestones; competitive weight-management treatments and absent clinical evidence are key risks.